SS-31 (Elamipretide)

Common side effects:

• Injection site erythema or redness
• Mild localized pruritus (itching)
• Temporary injection site swelling
• Mild headache
• Dizziness or lightheadedness

Rare or serious side effects:

• Hypersensitivity or allergic reactions
• Unexplained fatigue or lethargy
• Changes in blood pressure
• Gastrointestinal distress

Mitochondrial targeting defines the primary mechanism of the SS-31 (Elamipretide) peptide, as it selectively penetrates cell membranes to reach the inner mitochondrial membrane (IMM). Once inside, it binds electrostatically and hydrophobically to cardiolipin, a unique phospholipid crucial for IMM curvature and protein complex stability. This interaction prevents cytochrome c peroxidase activity, ensuring that cytochrome c remains an electron carrier rather than a generator of reactive oxygen species.

Cellular energy restoration occurs as a direct result of this structural stabilization. By optimizing the electron transport chain, SS-31 enhances ATP synthesis while simultaneously reducing pathological oxidative stress. This dual action preserves cellular viability in highly metabolic tissues, such as the retina and kidneys, particularly under ischemic or toxic conditions.

Synthetic development of SS-31 (Elamipretide) originated from research into Szeto-Schiller (SS) peptides, a novel class of compounds engineered for targeted mitochondrial delivery. Initially synthesized to combat oxidative stress, the peptide quickly demonstrated unique cardiolipin-binding properties that distinguished it from traditional antioxidants. Early preclinical success propelled the compound, also known as Bendavia, into extensive research for age-related and metabolic conditions.

Clinical trial progression has marked the regulatory journey of this peptide, though it currently remains an investigational drug without full FDA approval. It has been evaluated in multiple human studies, including completed Phase 2 trials for Friedreich's Ataxia (ClinicalTrials.gov, NCT05168774). Ongoing research continues to assess SS-31 (Elamipretide) benefits and safety profiles for various mitochondrial myopathies and ophthalmic diseases.